RobertMDS Patient

The Right Expression Can Change a Life

When genes are expressed at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By developing small-molecule medicines to control gene expression, we aim to make a profound difference in patients’ lives. We are currently developing tamibarotene for MDS patients with RARA gene overexpression.

Tamibarotene for HR-MDS

Tamibarotene (formerly SY-1425) is an oral selective retinoid acid receptor alpha (RARα) agonist in clinical development for patients with higher-risk myelodysplastic syndrome with RARA gene overexpression.

View Program

SY-2101

SY-2101 is a novel oral form of arsenic trioxide (ATO) previously in clinical development for patients with acute promyelocytic leukemia.

View Program

SY-5609

SY-5609 is a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor previously in clinical development for patients with pancreatic cancer.

View Program

Interested in Externally Sponsored Research?

Externally Sponsored Research (ESR) can play a role in expanding the knowledge related to a company product and/or its associated disease area(s). Syros encourages submissions from qualified investigators by filling out our form. Once submitted, a member of our medical affairs team will contact you with information on our review process.

Submit Your Request

Interested in Participating in a Clinical Trial?

If you’re interested in participating in a clinical trial, check to see if a trial is open near your area and if you meet the requirements to participate.

Learn More

Partnership Opportunities

We seek partnerships that maximize value for our partners and us. Please contact us to learn more about out-licensing opportunities.

View Our Partnership Focus

Our Publications and Abstracts

Learn more about the science and data behind our platform and our programs.

Read Publications and Abstracts